Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for ARCT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 191.48M
March 31, 2026 211.38M
December 31, 2025 230.91M
September 30, 2025 235.36M
June 30, 2025 251.47M
March 31, 2025 255.45M
December 31, 2024 292.03M
September 30, 2024 292.18M
June 30, 2024 315.33M
March 31, 2024 343.40M
December 31, 2023 347.00M
September 30, 2023 346.92M
June 30, 2023 378.47M
March 31, 2023 327.94M
December 31, 2022 391.88M
September 30, 2022 237.68M
June 30, 2022 283.49M
March 31, 2022 319.68M
December 31, 2021 370.49M
September 30, 2021 413.88M
June 30, 2021 433.57M
March 31, 2021 466.84M
December 31, 2020 462.90M
September 30, 2020 307.02M
June 30, 2020 136.11M
Date Value
March 31, 2020 59.47M
December 31, 2019 71.35M
September 30, 2019 74.17M
June 30, 2019 55.84M
March 31, 2019 31.22M
December 31, 2018 36.71M
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017 48.74M
September 30, 2017 39.82M
June 30, 2017 41.19M
March 31, 2017 45.25M
December 31, 2016 50.24M
September 30, 2016 51.35M
June 30, 2016 53.08M
March 31, 2016 53.23M
December 31, 2015 50.84M
September 30, 2015 35.51M
June 30, 2015 41.09M
March 31, 2015
December 31, 2014 21.70M
September 30, 2014 29.44M
June 30, 2014 38.94M
March 31, 2014 44.42M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 839.38M
PTC Therapeutics, Inc. 2.229B
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B
Anika Therapeutics, Inc. 38.41M